Welcome to our dedicated page for Adicet Bio news (Ticker: ACET), a resource for investors and traders seeking the latest updates and insights on Adicet Bio stock.
Adicet Bio, Inc. (Nasdaq: ACET) is a clinical-stage biotechnology company developing allogeneic gamma delta CAR T cell therapies for autoimmune diseases and cancer. The ACET news feed on Stock Titan aggregates company-issued updates, SEC-linked announcements, and other coverage related to Adicet’s clinical programs, capital markets activity, and regulatory interactions.
Investors and followers of Adicet Bio can use this page to review news on its lead program, prulacabtagene leucel (prula-cel, formerly ADI-001), an investigational allogeneic gamma delta CAR T therapy targeting B cells via an anti-CD20 CAR. Company releases have highlighted Phase 1 data in lupus nephritis and systemic lupus erythematosus, enrollment across additional autoimmune indications such as systemic sclerosis, idiopathic inflammatory myopathy, stiff person syndrome, ANCA associated vasculitis and treatment-refractory rheumatoid arthritis, and regulatory designations including Fast Track status for several of these conditions.
The ACET news stream also reflects Adicet’s oncology work, including updates on ADI-212, a next-generation, gene-edited and armored gamma delta CAR T candidate targeting prostate-specific membrane antigen in metastatic castration-resistant prostate cancer. Preclinical data presentations, plans for regulatory filings, and development timelines are typically communicated through press releases and associated 8-K filings.
Beyond clinical and scientific developments, Adicet Bio’s news includes information on registered direct offerings of common stock and pre-funded warrants, reverse stock split decisions, Nasdaq listing status notices, workforce and pipeline prioritization actions, and participation in healthcare conferences. By reviewing this curated ACET news page, readers can follow how Adicet reports progress in its autoimmune and oncology pipelines, how it manages its capital structure, and how key milestones are communicated through official channels.
Adicet Bio (Nasdaq: ACET) provided a corporate update highlighting 2026 milestones: the company reached FDA alignment to allow outpatient dosing of prulacabtagene leucel (prula-cel) for SLE and LN, all seven Phase 1 autoimmune cohorts are actively enrolling with over 20 patients as of Dec 31, 2025, and the first AAV patient was dosed. A Phase 1 clinical update is planned in 1H 2026 with an additional update in 2H 2026. Adicet expects to submit a regulatory filing for ADI-212 for mCRPC in 1H 2026 and raised approximately $74.8 million net in October 2025, extending cash runway into 2H 2027.
Adicet Bio (Nasdaq: ACET) announced a one-for-16 reverse stock split of common stock, effective 12:01 a.m. ET on December 30, 2025, with trading on a split-adjusted basis beginning at the open on December 30, 2025.
The reverse split will combine every sixteen issued shares into one, reducing outstanding shares from approximately 153.3 million to approximately 9.6 million. Authorized shares remain at 300,000,000, which the company says increases the number of shares available for future issuance. Proportional adjustments will be made to equity awards, options, conversions, and pre-funded warrants; fractional shares will be settled for cash. The company intends the split to help regain compliance with Nasdaq's minimum bid price requirement.
Adicet Bio (Nasdaq: ACET) announced an inducement equity award on November 28, 2025. The company granted a new-hire non-qualified stock option to purchase 20,600 shares at an exercise price of $0.65 per share, equal to the Nasdaq closing price on November 28, 2025. Vesting is one-fourth on the one-year anniversary and the remaining three-fourths in 36 substantially equal monthly installments, resulting in full vesting on the fourth anniversary, subject to continued employment.
The award was granted outside the company’s stockholder-approved plans under Adicet’s 2022 Inducement Plan (amended January 2023) and was authorized by the compensation committee as a material inducement under Nasdaq Listing Rule 5635(c)(4).
Adicet Bio (NASDAQ: ACET) reported Q3 2025 results and clinical updates on November 5, 2025. The company announced positive preliminary Phase 1 safety and efficacy data for ADI-001 in seven lupus nephritis (LN) and SLE patients, including rapid SLEDAI-2K and PGA reductions, improved renal function with three complete renal responses and DORIS remissions, emergence of a naïve B cell repertoire, and no Grade 2+ CRS or ICANS as of the August 31, 2025 cut-off. Adicet plans an FDA meeting in 1Q/2026 and anticipates starting a potentially pivotal ADI-001 study in 2Q/2026. The company raised $74.8M net in October, extending cash runway into 2H/2027. Q3 net loss was $26.9M and cash on Sept 30 was $103.1M.
Adicet Bio (Nasdaq: ACET) granted inducement awards on October 31, 2025 to five employees hired in October 2025. In aggregate, the company issued non-qualified stock options to purchase 97,200 shares at an exercise price of $0.75 per share (Nasdaq closing price on October 31, 2025).
The options vest 25% after one year and the remaining 75% monthly over 36 months, with full vesting on the fourth anniversary of each hire subject to continued employment. Awards were granted outside the company’s stockholder-approved plans under Adicet’s 2022 Inducement Plan and were authorized by the compensation committee as an inducement under Nasdaq Listing Rule 5635(c)(4).
Adicet Bio (Nasdaq: ACET) announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston on November 11, 2025 at 3:00 p.m. ET.
The event runs November 10–12, 2025. A live audio webcast will be available on the company's Investors website and an archived replay will be accessible for 30 days after the presentation.
Adicet Bio (Nasdaq: ACET) announced the first patient has been dosed in its Phase 1 trial of ADI-001 for treatment-refractory rheumatoid arthritis (RA) on October 16, 2025. The program is enrolling across seven autoimmune conditions and will test two conditioning regimens: cyclophosphamide alone and cyclophosphamide plus fludarabine. Preliminary clinical data are expected in 2H/2026. The company cited prior promising safety and efficacy findings for ADI-001 in lupus nephritis and systemic lupus erythematosus as encouragement for broader autoimmune potential.
Adicet Bio (Nasdaq: ACET) announced an underwritten registered direct offering expected to raise approximately $80.0 million in gross proceeds. The company is selling 70,001,000 shares of common stock at $1.00 per share and, to certain investors, pre-funded warrants exercisable for 10,000,000 shares priced at $0.9999 each (exercise price $0.0001 per warrant).
The offering is expected to close on or about October 8, 2025, subject to customary conditions, and is being underwritten by Jefferies, Guggenheim Securities, Truist Securities, Wedbush PacGrow, and H.C. Wainwright. Securities are offered under an S-3 shelf registration declared effective March 14, 2025.
Adicet Bio (Nasdaq: ACET) reported positive preliminary Phase 1 data for ADI-001 in lupus nephritis (LN) and systemic lupus erythematosus (SLE) as of the August 31, 2025 data cut-off. All seven evaluable patients (five LN, two SLE) showed rapid, sustained SLEDAI-2K and PGA score reductions and immune reset signals after a single dose. All five LN patients achieved renal responses (three complete responses with DORIS remissions, two partial responses), with responses ongoing. ADI-001 was generally well tolerated (no SAEs, no ICANS, two Grade 1 CRS, one Grade 1 infection). More than 25 sites are open; Adicet plans an FDA meeting in 1Q/2026 and anticipates a pivotal study start in 2Q/2026.
Adicet Bio (Nasdaq: ACET), a clinical-stage biotech company focused on allogeneic gamma delta T cell therapies, has granted an inducement award to a new employee. The award consists of non-qualified stock options to purchase 9,800 shares at an exercise price of $0.81 per share.
The stock options will vest over four years, with 25% vesting after one year and the remaining 75% vesting in 36 monthly installments. The award was granted under Adicet's 2022 Inducement Plan and approved by the compensation committee as a material inducement for employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
FAQ
What is the current stock price of Adicet Bio (ACET)?
What is the market cap of Adicet Bio (ACET)?
